MicroRNA-155 Suppresses Mesangial Cell Proliferation and TGF-β1 Production via Inhibiting CXCR5-ERK Signaling Pathway in Lupus Nephritis

Kong, Jie; Li, Liuxia; Lu, Zhimin; Song, Jing; Yan, Jiaxin; Yang, Junling; Gu, Zhifeng; Da, Zhanyun

doi:10.1007/s10753-018-0889-1

Cited by 26 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ERK expression is increased in several immune diseases. 15,16 In our study, we showed that ACL titers significantly decreased under BRAF or MEK inhibitors. We cannot draw any conclusions about a specific effect of the MAPK pathway inhibition, or an anti-inflammatory effect on histiocytes.…”

Section: Before Treatment Last Determination Acl Titers (Ui/l)supporting

confidence: 48%

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors

Roeser¹,

Cohen‐Aubart²,

Breillat³

et al. 2019

Haematologica

View full text Add to dashboard Cite

Section: Before Treatment Last Determination Acl Titers (Ui/l)supporting

confidence: 48%

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors

Roeser¹,

Cohen‐Aubart²,

Breillat³

et al. 2019

Haematologica

View full text Add to dashboard Cite

“…The exact mechanism underlying miR-155-mediated SLE development remains unclear. Jie et al found that miR-155 inhibits the proliferation of mesangial cells and decreases the production of TGF-β1 in LN ( 24 ). Qian et al reported that miR-155 deficiency ameliorates autoimmune inflammation in SLE by targeting sphingosine-1-phosphate receptor 1 ( 25 ).…”

Section: Discussionmentioning

confidence: 99%

Circulating Exosomal microRNAs as Biomarkers of Systemic Lupus Erythematosus

Li¹,

Liu²,

Chen³

et al. 2020

Clinics

View full text Add to dashboard Cite

OBJECTIVES: Many studies indicate that microRNAs (miRNAs) could be potential biomarkers for various diseases. The purpose of this study was to investigate the clinical value of serum exosomal miRNAs in systemic lupus erythematosus (SLE). METHODS: Serum exosomes were isolated from 38 patients with SLE and 18 healthy controls (HCs). The expression of miR-21, miR-146a and miR-155 within exosomes was examined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Using receiver operating characteristic (ROC) curves, we evaluated the diagnostic value of exosomal miRNAs. RESULTS: Exosomal miR-21 and miR-155 were upregulated ( p <0.01), whereas miR-146a expression ( p <0.05) was downregulated in patients with SLE, compared to that in HCs. The expression of miR-21 ( p <0.01) and miR-155 ( p <0.05) was higher in SLE patients with lupus nephritis (LN) than in those without LN (non-LN). The analysis of ROC curves revealed that the expression of miR-21 and miR-155 showed a potential diagnostic value for LN. Furthermore, miR-21 (R=0.44, p <0.05) and miR-155 (R=0.33, p <0.05) were positively correlated with proteinuria. The expression of miR-21 was negatively associated with anti-SSA/Ro antibodies (R=−0.38, p <0.05), and that of miR-146a was negatively associated with anti-dsDNA antibodies (R=−0.39, p <0.05). CONCLUSIONS: These findings suggested that exosomal miR-21 and miR-155 expression levels may serve as potential biomarkers for the diagnosis of SLE and LN.

show abstract

“…Krebs et al found that miR-155 stimulation in experimental crescentic glomerulonephritis resulted in accelerated kidney injury through T H 17 immunity [ 8 ]. However, another study reported that miR-155 decreased the proliferation of mesangial cells in lupus nephritis, which indicates the renoprotective characteristics of miR-155 [ 9 ]. Nevertheless, the actual relationship between miR-155 and renal disease may be much more complex.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of miRNA-155 Alleviates High Glucose-Induced Podocyte Inflammation by Targeting SIRT1 in Diabetic Mice

Wang

Gao

et al. 2021

Journal of Diabetes Research

View full text Add to dashboard Cite

Objective. Microinflammation plays a crucial role in podocyte dysfunction in diabetic nephropathy, but its regulatory mechanism is still unclear. This study is aimed at discussing the mechanisms underlying the effect of miRNA-155 on podocyte injury to determine its potential as a therapeutic target. Methods. Cultured immortalized mouse podocytes and diabetic KK-Ay mice models were treated with a miR-155 inhibitor. Western blotting, real-time PCR, ELISA, immunofluorescence, and Luciferase reporter assay were used to analyze markers of inflammation cytokines and podocyte injury. Results. miRNA-155 was found to be highly expressed in serum and kidney tissue of mice with diabetic nephropathy and in cultured podocytes, accompanied by elevated levels of inflammatory factors. Inhibition of miRNA-155 can reduce proteinuria and ACR levels, diminish the secretion of inflammatory molecules, improve kidney function, inhibit podocyte foot fusion, and reverse renal pathological changes in diabetic nephropathy mice. Overexpression of miRNA-155 in vitro can increase inflammatory molecule production in podocytes and aggravates podocyte injury, while miRNA-155 inhibition suppresses inflammatory molecule production in podocytes and reduces podocyte injury. A luciferase assay confirmed that miRNA-155 could selectively bind to 3 ′ -UTR of SIRT1, resulting in decreased SIRT1 expression. In addition, SIRT1 siRNA could offset SIRT1 upregulation and enhance inflammatory factor secretion in podocytes, induced by the miRNA-155 inhibitor. Conclusions. These findings strongly support the hypothesis that miRNA-155 inhibits podocyte inflammation and reduces podocyte injury through SIRT1 silencing. miRNA-155 suppression therapy may be useful for the management of diabetic nephropathy.

show abstract

MicroRNA-155 Suppresses Mesangial Cell Proliferation and TGF-β1 Production via Inhibiting CXCR5-ERK Signaling Pathway in Lupus Nephritis

Cited by 26 publications

References 34 publications

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors

Circulating Exosomal microRNAs as Biomarkers of Systemic Lupus Erythematosus

Inhibition of miRNA-155 Alleviates High Glucose-Induced Podocyte Inflammation by Targeting SIRT1 in Diabetic Mice

Contact Info

Product

Resources

About